| 本文已被：浏览 2190次 下载 1927次 |
码上扫一扫！ |
| eEF1A1在T1N0M0期肾癌中的表达及与预后的关系 |
| 鲍一1△,王志向1△,李鹏1,陈俊明1,刘冰1,杨庆2,高莉3,吴震杰1,王林辉1* |
|
|
(1. 第二军医大学长征医院泌尿外科, 上海 200003;
2. 第二军医大学长海医院泌尿外科, 上海 200433;
3. 第二军医大学长海医院病理科, 上海 200433
△共同第一作者
*通信作者) |
|
| 摘要: |
| 目的 探讨真核延伸因子1A1(eEF1A1)在T1N0M0期肾癌组织中的表达及其与预后的关系. 方法 收集第二军医大学长海医院泌尿外科在2007年行手术治疗的患者标本共70例.入选标准:术前未进行其他治疗,TNM分期为T1N0M0,行肾癌根治术,病理为透明细胞癌,患者及随访资料完整.通过免疫组化技术检测手术标本中癌组织eEF1A1的表达量,建立eEF1A1表达量与Fuhrman病理分级和预后之间的对应关系,绘制交叉表,通过χ2检验、Fisher精确概率法研究eEF1A1和肾癌Fuhrman病理分级的关系.通过绘制Kaplan-Meier生存曲线并进行log-rank检验研究eEF1A1和T1N0M0期肾癌预后的关系. 结果 随访时间为4~95个月,平均(77.9±18.3)个月,随访期内总生存率为88.6%,无进展生存率为80.0%.免疫组化显示eEF1A1在61.4%的肾癌组织中高表达,并且在高Fuhrman分级的肾癌组织中高表达(P=0.004).生存分析提示肾癌组织低表达eEF1A1的患者生存期较长(P=0.019),并且癌组织中低表达eEF1A1的患者均存活. 结论 T1N0M0期肾癌组织中eEF1A1表达与肿瘤Fuhrman病理分级及患者预后有关,表达量低的患者预后较好. |
| 关键词: 肾肿瘤 肿瘤分期 真核延伸因子1A1 预后 |
| DOI：10.3724/SP.J.1008.2015.00734 |
| 投稿时间：2015-04-14修订日期：2015-06-14 |
| 基金项目:国家自然科学基金(81272817). |
|
| Expression of eukaryotic elongation factor 1A1 in renal cell carcinoma of T1N0M0 stage and its relationship with prognosis |
| BAO Yi1△,WANG Zhi-xiang1△,LI Peng1,CHEN Jun-ming1,LIU Bing1,YANG Qing2,GAO Li3,WU Zhen-jie1,WANG Lin-hui1* |
(1. Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China;
2. Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China;
3. Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
△Co-first authors.
*Corresponding author) |
| Abstract: |
| Objective To study the expression of eukaryotic elongation factor 1A1 (eEF1A1) in T1N0M0 renal cancer tissues and its relationship with patient prognosis. Methods The tissue specimens of patients with renal cell carcinoma who received radical nephrectomy in Shanghai Changhai Hospital in 2007 were collected. Inclusion criteria were: no treatments before surgery, T1N0M0 stage, clear cell carcinoma and with complete follow-up data. Immunohistochemical staining was used to examine the expression of eEF1A1 in the cancerous tissues, and we then established the relationship of eEF1A1 expression with Fuhrman pathological grading and patient prognosis. The relationship between Fuhrman grading pathological staging and eEF1A1 expression was investigated by drawing crosstabs, chi-square test, and Fisher's exact test. Kaplan-Meier survival curves and log-rank test were used to study the relationship between eEF1A1 and prognosis of patients with T1N0M0 renal cell carcinoma. Results The patients were followed up for 4-95 months, averagely (77.9±18.3) months; the overall survival rate of patients was 88.6% and the progression-free survival rate was 80.0% during the follow-up period. Immunohistochemistry showed eEF1A1 was highly expressed in 61.4% of renal cell carcinoma tissues and in tissues of high Fuhrman grade (P=0.004). Survival analysis showed patients with low expression of eEF1A1 in renal cell carcinoma tissue had significantly longer survival (P=0.019), and all the patients with low expression survived in our study. Conclusion Expression of eEF1A1 in T1N0M0 renal cell carcinoma tissue is associated with Fuhrman grades and prognosis, with low expression indicating a better prognosis. |
| Key words: kidney neoplasms neoplasm staging eukaryotic elongation factor 1A1 prognosis |
